Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: if_vaccine_received Yes/vaccine_brand=Pfizer / BioNTech/product=COVID 19 Treatment, brand=Paxlovid; if_vaccine_received Yes/vaccine_brand=Pfizer / BioNTech/product=COVID 19 Treatment, brand=Paxlovid; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71-year-old male patient received BNT162b2 (BNT162B2), on 07Jan2021 as dose 1, single (Lot number: EL1284), in left arm, on 21Jan2021 as dose 2, single (Lot number: EL9262), in left arm and on 25Aug2021 as dose 3 (booster), single (Lot number: FC3183) at the age of 70 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 29Jan2022 as dose 4 (booster), single (Lot number: 007J21ZA), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Other medical history: Diabetic type 2" (unspecified if ongoing), notes: Other medical history: Diabetic type 2, high blood pressure, stroke, heart flutter; "Other medical history: high blood pressure" (unspecified if ongoing), notes: Other medical history: Diabetic type 2, high blood pressure, stroke, heart flutter; "Other medical history: stoke" (unspecified if ongoing), notes: Other medical history: Diabetic type 2, high blood pressure, stroke, heart flutter; "Other medical history: heart flutter" (unspecified if ongoing), notes: Other medical history: Diabetic type 2, high blood pressure, stroke, heart flutter; "Known allergies: Possibly Penicillin" (unspecified if ongoing), notes: Known allergies: Possibly Penicillin. Concomitant medication(s) included: METFORMIN, start date: Sep2007; LISINOPRIL; VIT D3; VIT B COMPLEX; ROSUVASTATIN; BAYER ASPIRIN. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 16Apr2022, outcome "unknown" and all described as "if_vaccine_received Yes/vaccine_brand=Pfizer / BioNTech/product=COVID 19 Treatment, brand=Paxlovid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (30Apr2022) Positive, notes: Positive on 30Apr and today 01May; (01May2022) Positive, notes: Positive on 30Apr and today 01May; (16Apr2022) Positive, notes: positive tests (both home test and PCR) on 16Apr; (16Apr2022) Positive, notes: positive tests (both home test and PCR) on 16Apr; (23Apr2022) Negative, notes: Negative rapid test on 23Apr; (25Apr2022) Positive, notes: Strong positive rapid tests on 25Apr, 26, 27; (26Apr2022) Positive, notes: Strong positive rapid tests on 25Apr, 26, 27; (27Apr2022) Positive, notes: Strong positive rapid tests on 25Apr, 26, 27. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course reported as patient took Paxlovid on 17Apr following first symptoms on 14Apr, and positive tests (both home test and PCR) on 16Apr. Negative rapid test on 23Apr which followed two days of faint positive tests. No test on 24Apr. Strong positive rapid tests on 25Apr, 26Apr, 27Apr. No test on 28Apr & 29Apr. Positive on 30Apr and today 01May. Anti-viral Paxlovid (lot number=FY4445) started on 17Apr2022 as treatment for COVID-19 and treatment stopped on 21Apr2022.